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Fanconi anemia (FA) is a genetically heterogeneous disorder with 22 disease-causing genes reported 
to date. in some fA genes, monoallelic mutations have been found to be associated with breast cancer 
risk, while the risk associations of others remain unknown. the gene for fA type c, FANCC, has been 
proposed as a breast cancer susceptibility gene based on epidemiological and sequencing studies. 
We used the oncoarray project to genotype two truncating FANCC variants (p.R185X and p.R548X) in 
64,760 breast cancer cases and 49,793 controls of European descent. FANCC mutations were observed 
in 25 cases (14 with p.R185X, 11 with p.R548X) and 26 controls (18 with p.R185X, 8 with p.R548X). 
There was no evidence of an association with the risk of breast cancer, neither overall (odds ratio 0.77, 
95%CI 0.44–1.33, p = 0.4) nor by histology, hormone receptor status, age or family history. We conclude 
that the breast cancer risk association of these two FANCC variants, if any, is much smaller than for 
BRCA1, BRCA2 or PALB2 mutations. if this applies to all truncating variants in FANCC it would suggest 
there are differences between FA genes in their roles on breast cancer risk and demonstrates the merit 
of large consortia for clarifying risk associations of rare variants.
Fanconi Anemia (FA) is a rare recessively inherited disorder characterized by congenital malformations, progres-
sive bone marrow failure and predisposition to cancer. Twenty-two different FA causative genes have now been 
identified whose products act in concert to mediate DNA interstrand crosslink repair1–3. At least seven of them 
(BRCA2/FANCD2, PALB2/FANCN, RAD51C/FANCO, RAD51/FANCR, BRCA1/FANCS, XRCC2/FANCU, and 
RFWD3/FANCW) are involved in different stages of homology-directed recombinational DNA repair (HRR), a 
pathway for error-free maintenance of the genome during replication and after DNA damage. A number of FA 
genes (including BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN) have been shown to be breast cancer 
susceptibility genes3. The products of BRCA1, BRCA2, and PALB2 are central to early stages of HRR. Further 
interactors in this pathway, in particular BRIP1/FANCJ, mainly have been linked to ovarian cancer risk4,5. It is less 
known to what extent other FA gene products may play a role in the inherited component of breast cancer suscep-
tibility. Few of these other FA genes have been tested for mutations in relatively small breast cancer case-control 
studies, thus far6–9.
Early studies suggested that blood relatives of FA patients show an increased risk of breast cancer, although 
these findings have not been corroborated in a replication study and could not assess distinct FA complemen-
tation groups due to lack of genetic information at that time10–13. After FA was stratified into subsets defined by 
complementation assays, an increased risk of breast cancer was attributed to heterozygous carriers of FANCC 
mutations13. Historically, this was the first of the FA genes to be identified and accounts for 8–15% of FA cases14–16. 
More recently, FANCC has been suggested as a candidate breast cancer susceptibility gene in an exome sequencing 
study of 33 familial breast cancer cases and extension to another 438 cases17. However, the evidence for an asso-
ciation between FANCC and breast cancer risk is limited by the low prevalence of mutations17,18, and much larger 
numbers of individuals are needed to provide sufficient power to detect associations of plausible magnitude19.
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In the present study, we genotyped two truncating variants of FANCC (p.R185X and p.R548X) using the 
Oncoarray (see Methods) in 64,760 female breast cancer cases and 49,793 female population controls of European 
descent. Both mutations are disease-causing in European FA patients and are recurrent in the FA mutation 
database20.
Results
We identified the truncating FANCC variants p.R185X (rs121917783) and p.R548X (rs104886457) in 40 of 
153,899 individuals and 20 of 153,904 individuals, respectively. All mutation carriers were heterozygotes. Carrier 
distributions per study and intensity cluster plots for Europeans (which included the majority of mutation car-
riers) are shown in Supplementary Table 1 and Supplementary Fig. 1, respectively. Since the majority of carriers 
were women of European ancestry, we restricted the subsequent case-control association analysis to participants 
from this population. Logistic regression analyses were adjusted for study and 15 principal components21.
In Europeans, the two FANCC variants were observed in 25/64,760 cases (14 with p.R185X, 11 with p.R548X) 
and in 26/49,793 controls (18 with p.R185X, 8 with p.R548X). There was no evidence of association between the 
FANCC variants and breast cancer risk, either for carriers of both variants combined (OR 0.77, 95%CI 0.44–1.33, 
p = 0.35), or for either variant individually (Table 1). Similarly, we found no evidence for an association with 
estrogen receptor (ER)-negative (OR 0.91, 0.35–2.37) or ER-positive (OR 0.67, 0.37–1.28) disease, nor for subsets 
of disease defined by age at diagnosis (<50 years), bilaterality, family history, histological morphology, grade or 
nodal status (Table 2).
For comparison, we also analysed the PALB2/FANCN*p.R414X truncating variant that was genotyped in par-
allel on the same array. This variant was detected in 22/64,780 cases and 3/49,825 controls and was significantly 
associated with risk of breast cancer (OR 5.89, 95%CI 1.76–19.74, p = 0.004). The variant carriers were markedly 
enriched among cases with ER-negative tumours (p = 9.4 × 10−6; pdiff = 0.0006 in a log-likelihood ratio test) and 
specifically triple-negative breast tumours (p = 3.8 × 10−7; pdiff = 0.0001). The p.R414X truncating variant was also 
associated with ductal morphology, a positive first-degree family history of breast cancer, early age at diagnosis 
(<50 years), and low-differentiated tumours (grade 3) (Suppl. Table 1). Hence, by contrast with the two tested 
FANCC variants, p.R185X and p.R548X, the FANCN/PALB2 variant p.R414X was strongly associated with overall 
and with ER-negative disease under the same genotyping and analysis conditions.
Discussion
Functional defects of DNA repair are a hallmark of genomic instability syndromes as well as of carcinogenesis. FA 
is a genome instability and cancer prone disorder that has been investigated for breast cancer predisposition in 
homozygotes and heterozygotes for more than three decades11,12. Monoallelic mutations in five FA genes (BRCA1, 
BRCA2, PALB2, RAD51C, BRIP1) have now been confirmed to predispose to breast or ovarian cancer while bial-
lelic mutations in these genes cause FA3. However, the role of the FA genes most commonly mutated, FANCA and 
FANCC, in the risk of developing breast cancer has remained uncertain. Epidemiological and segregation studies 
have provided some evidence of an increased breast cancer risk for grandmothers of FA patients, particularly 
those who carry the FANCC mutation13.
A previous sequencing study of Australian multiple-case breast cancer families had identified truncating var-
iants in FANCC in 3 of 438 multiple-case breast cancer families but in none of 464 healthy controls, suggestive 
of a predisposing role for FANCC variants in breast cancer17. One of these variants, p.R185X, was also screened 
in our study. p.R185X was first reported shortly after the identification of the FANCC gene, and thus is one of 
the earliest recognized FA-causing mutations. Although representing an apparent nonsense mutation in exon 6, 
it also results in exon 6 being spliced out of a proportion of transcripts, suggesting this variant may alter splice 
site selection, with the aberrant transcript retaining the reading frame22. p.R548X, also an early-detected FANCC 
truncating variant23, is an authentic stop mutation in exon 14, and although in the last exon, it proved to be clearly 
pathogenic for FA24.
The fact that these two disease-causing variants have been frequently observed in European patients with 
FA20 prompted us to investigate their association with breast cancer in a large case-control study. However, we 
did not observe a significant difference between their frequency among breast cancer cases and controls. The 
upper 95% confidence limit was 1.33, thus excluding a two-fold or greater increase in risk found for moderate- or 
high-penetrance alleles in predisposition genes such as CHEK2 and ATM. Moreover, we found no evidence of 
association in subgroups defined by earlier age at onset, a positive family history of breast cancer, bilateral occur-
rence, or defined tumor parameters (histology, grade or hormone receptor status). However, confidence intervals 
for those estimates for subsets were wider as numbers were small – in particular we could not rule out a 2-fold 
increased risk for ER-negative or triple-negative breast cancer.
In contrast, we observed a clear association between the PALB2/FANCN variant p.R414X and breast cancer 
risk. PALB2 is an established breast cancer susceptibility gene, and the investigated mutation p.R414X25 occurred 
Mutation Cases Controls Odds Ratio (95% CI) p
p.R158X 14/64,778 18/49,810 0.64 (0.32; 1.29) 0.215
p.R548X 11/64,788 8/49,816 1.03 (0.41; 2.56) 0.942
All FANCC 25/64,760 26/49,793 0.77 (0.44; 1.33) 0.345
Table 1. Overall analysis of FANCC variants p.R158X and p.R548X. Association analyses of FANCC variants 
p.R158X and p.R548X with overall breast cancer risk. Results are given as odds ratios (OR) with 95% confidence 
interval (CI) and p-value (p).
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at a similar frequency to the tested FANCC mutations. The observed six-fold enrichment of p.R414X in breast 
cancer patients is in line with previous findings for other PALB2 founder mutations26–28 and in the upper range of 
the overall mutational effect size in PALB2 case-control sequencing studies29,30. We confirmed stronger associa-
tions with ER-negative breast cancer, with familial breast cancer and with a high tumor grade31. While genotyping 
arrays such as the Oncoarray are primarily used for evaluating common variants, these data confirm that the 
array provides a robust platform for evaluating even very rare alleles.
Although PALB2 and FANCC are both FA genes, their products exert different roles in the recognition 
and repair of DNA damage. FANCC is a component of the FA core complex which is thought to recognize an 
inter-strand crosslink. FANCL, an E3 ubiquitin ligase in the core complex, ubiquitinates FANCI and FANCD2. 
After many nuclease and translesion polymerase steps, a DNA double stranded intermediate is formed and its 
repair requires proteins from the homology-directed repair pathway, including FANCD1/BRCA2 and FANCN/
PALB2. While truncating variants in BRCA2 and PALB2 confer a substantial risk of breast cancer, our study sug-
gests that truncating FANCC variants do not confer a comparable risk. It is possible that members of the FA core 
complex that act upstream of HRR are less relevant for breast cancer due to their more specialized function in the 
repair of crosslinks while BRCA1, BRCA2, and PALB2 function more globally at DNA double-strand breaks. On 
the other hand, there is some evidence that truncating mutations in another gene involved in the early detection 
of intra-strand crosslinks, FANCM, are associated with both breast and ovarian cancer risk32–34, though FANCM 
is part of an anchor complex rather than the FA core complex and is not considered a classical FA gene35,36. It is 
also possible that the two prototype FANCC truncating variants analysed here, despite being FA-causing, have 
reduced penetrance for breast cancer due to some residual function, and other particular FANCC variants may 
confer a more substantial risk. More work will be required to clarify the role of each FA core complex member for 
breast cancer susceptibility.
In conclusion, our study findings suggest important differences between FA genes, indicating that truncating 
variants in FANCC do not confer a high overall risk of breast cancer unlike PALB2, BRCA1 and BRCA2. Our 
study does not exclude a role of monoallelic FANCC variants as low-penetrance alleles for breast cancer or as a 
genetic risk factor for certain breast cancer subgroups. Very large datasets, such as those generated through the 
BCAC, are critical to evaluate such rare mutations.
Methods
patients. A total of 87 studies from the Breast Cancer Association Consortium (BCAC), of which 78 were 
case-control studies (some nested within prospective cohort studies) and 9 were case-only studies, contributed 
data as summarized in Supplementary Table 1. All studies provided data on disease status and age at diagnosis/
observation, and the majority provided information on clinico-pathological and epidemiological factors, which 
have been curated and incorporated into the BCAC database (version 6). All participating studies were approved 
by their appropriate ethics review boards and all subjects provided informed consent. A list of the ethics review 
boards by study is provided in Supplementary Table 3.
Genotyping. The Illumina OncoArray design and genotyping procedure have been described previously21,37. 
In brief, approximately 72,000 variants were selected, among others, for inclusion on the array specifically for 
their potential relevance to breast cancer, based on prior evidence of association with overall or subtype-specific 
disease, with breast density or with breast tissue specific gene expression. After genotype calling and quality 
control of the cluster file, variants with a call rate <95% in any consortium, not in Hardy-Weinberg equilib-
rium (P < 10−7 in controls or P < 10−12 in cases) or with concordance <98% among 5,280 duplicate pairs were 
excluded. We also excluded samples with extreme heterozygosity (>4.89 standard deviations [SD] from the mean 
for the respective ethnicity). The final dataset, before restriction based on ethnicity, consisted of 153,673 samples 
of which 89,733 were cases and 63,940 were controls.
Stratum Cases Odds Ratio (95% CI) p
ER-negative 5/10,124 0.91 (0.35; 2.37) 0.845
ER-positive 14/40,855 0.67 (0.37; 1.28) 0.223
TNBC 2/4,126 0.89 (0.21; 3.77) 0.877
Ductal 6/36,695 0.33 (0.13; 0.80) 0.014
Lobular 4/6,842 1.27 (0.43; 3.69) 0.665
High grade 3/14,582 0.39 (0.12; 1.31) 0.129
Node-positive 1/15,937 0.14 (0.02; 1.00) 0.050
Familial 7/9,720 1.01 (0.43; 2.35) 0.988
Premenopausal 12/22,232 1.09 (0.55; 2.16) 0.814
Bilateral 0/2,741 — 0.645
Table 2. Analysis of FANCC variants (p.R158X and p.R548X combined) by tumour subtype. Association 
analyses of FANCC variants p.R158X and p.R548X with breast cancer risk for subgroups. Results are given as 
odds ratios (OR) with 95% confidence interval (CI) and p-value (p). Cases in subgroups were compared to the 
frequency 26/ 49,793 for all controls (derived from Table 1). Familial cases were defined as those with a first-
degree family history of breast cancer; premenopausal cases were those with age at diagnosis <50 years. ER, 
estrogen-receptor; TNBC, triple-negative breast cancer.
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Statistical analyses. Per-allele odds ratios and 95% confidence intervals were generated using logis-
tic regression with adjustment for principal components and study. Principal component analysis was per-
formed using data for 33,661 uncorrelated SNPs (which included 2,318 markers of continental ancestry) with a 
MAF ≥ 0.05 and maximum correlation of 0.1, using purpose-written PCcalc software (written by Jonathan Tyrer 
and available at http://ccge.medschl.cam.ac.uk/software/pccalc/).
We also estimated subtype-specific per-allele ORs after restricting the cases by hormone receptor and/or 
HER2/neu status, by tumor grade, by ductal or lobular morphology, by nodal status, by bilateral occurrence of the 
tumor, by early diagnosis (<50 years), and by first-degree family history of breast cancer, using available BCAC 
data for the cases. Since we analysed 3 variants across 10 subgroups, a two-sided p-value ≤ 0.016 for the overall 
analyses and a two-sided p-value ≤ 0.0016 for the subgroup analyses were considered nominally significant.
ethical approval. All experimental protocols were approved by the respective ethical institutions of partic-
ipating BCAC centers. The study was carried out in accordance with the Declaration of Helsinki, and informed 
consent was obtained from all study participants.
Data Availability
The genotyping results from the Oncoarray are available in the dbGAP repository. The FANCC variants analysed 
in the current study are deposited in the NCBI SNP database as rs121917783 and rs104886457. The datasets an-
alysed during the current study are available from the corresponding author upon reasonable request and with 
permission of the Data Access Committee of the Breast Cancer Association Consortium.
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